- Home
- GSL vs CRMD Comparison
GSL vs CRMD Comparison
Compare GSL & CRMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GSL
- CRMD
- Stock Information
- Founded
- GSL 2007
- CRMD 2006
- Country
- GSL Greece
- CRMD United States
- Employees
- GSL N/A
- CRMD N/A
- Industry
- GSL Marine Transportation
- CRMD Biotechnology: Pharmaceutical Preparations
- Sector
- GSL Consumer Discretionary
- CRMD Health Care
- Exchange
- GSL Nasdaq
- CRMD Nasdaq
- Market Cap
- GSL 886.8M
- CRMD 973.3M
- IPO Year
- GSL 2006
- CRMD 2010
- Fundamental
- Price
- GSL $26.05
- CRMD $13.61
- Analyst Decision
- GSL Strong Buy
- CRMD Strong Buy
- Analyst Count
- GSL 1
- CRMD 7
- Target Price
- GSL $30.00
- CRMD $15.29
- AVG Volume (30 Days)
- GSL 370.2K
- CRMD 1.4M
- Earning Date
- GSL 08-04-2025
- CRMD 08-13-2025
- Dividend Yield
- GSL 8.05%
- CRMD N/A
- EPS Growth
- GSL 20.64
- CRMD N/A
- EPS
- GSL 10.54
- CRMD 0.28
- Revenue
- GSL $715,232,000.00
- CRMD $82,553,827.00
- Revenue This Year
- GSL $3.22
- CRMD $238.38
- Revenue Next Year
- GSL N/A
- CRMD $53.52
- P/E Ratio
- GSL $2.54
- CRMD $48.60
- Revenue Growth
- GSL 3.83
- CRMD N/A
- 52 Week Low
- GSL $17.73
- CRMD $3.61
- 52 Week High
- GSL $30.19
- CRMD $15.38
- Technical
- Relative Strength Index (RSI)
- GSL 59.71
- CRMD 57.69
- Support Level
- GSL $25.96
- CRMD $13.83
- Resistance Level
- GSL $26.66
- CRMD $14.99
- Average True Range (ATR)
- GSL 0.57
- CRMD 0.69
- MACD
- GSL -0.03
- CRMD -0.14
- Stochastic Oscillator
- GSL 65.35
- CRMD 45.71
About GSL Global Ship Lease Inc New
Global Ship Lease Inc operates in the container shipping industry. The company owns and charters out containerships under long-term, fixed-rate charters to container liner companies. The majority of the company's revenues are derived from charters to MAERSK. Its fleet consisted of more than 60 containerships.
About CRMD CorMedix Inc.
Cormedix Inc is a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions. The Company's focus is on the commercialization of its product, DefenCath, in the United States (U.S.) and other key markets. The group currently operates in a single segment, Drug Product, located in a single geographic location, the United States.